Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Assessing tumor hypoxia by positron emission tomography with Cu-ATSM.

Holland JP, Lewis JS, Dehdashti F.

Q J Nucl Med Mol Imaging. 2009 Apr;53(2):193-200. Review.

2.

A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].

Furukawa T, Yuan Q, Jin ZH, Aung W, Yoshii Y, Hasegawa S, Endo H, Inoue M, Zhang MR, Fujibayashi Y, Saga T.

Oncol Rep. 2015 Sep;34(3):1379-87. doi: 10.3892/or.2015.4079. Epub 2015 Jun 25.

PMID:
26134305
3.

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.

O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL.

Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1493-502.

PMID:
15817355
4.

Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.

Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA.

Dis Colon Rectum. 2008 Nov;51(11):1641-8. doi: 10.1007/s10350-008-9420-3. Epub 2008 Aug 6.

5.

Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).

Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW.

J Nucl Med. 2006 Jun;47(6):989-98.

6.

Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.

Bonnitcha PD, Bayly SR, Theobald MB, Betts HM, Lewis JS, Dilworth JR.

J Inorg Biochem. 2010 Feb;104(2):126-35. doi: 10.1016/j.jinorgbio.2009.10.009. Epub 2009 Oct 24.

7.

Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.

Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1233-8.

PMID:
12654432
8.

A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.

Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ.

Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1171-82.

PMID:
11240261
9.

A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers.

Carlin S, Zhang H, Reese M, Ramos NN, Chen Q, Ricketts SA.

J Nucl Med. 2014 Mar;55(3):515-21. doi: 10.2967/jnumed.113.126615. Epub 2014 Feb 3.

10.

Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.

Kinoshita T, Fujii H, Hayashi Y, Kamiyama I, Ohtsuka T, Asamura H.

Lung Cancer. 2016 Jan;91:56-66. doi: 10.1016/j.lungcan.2015.11.020. Epub 2015 Nov 28.

PMID:
26711935
11.

PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions.

Zhang T, Das SK, Fels DR, Hansen KS, Wong TZ, Dewhirst MW, Vlahovic G.

AJR Am J Roentgenol. 2013 Nov;201(5):W698-706. doi: 10.2214/AJR.12.9698.

12.

Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia.

Vāvere AL, Lewis JS.

Dalton Trans. 2007 Nov 21;(43):4893-902. Epub 2007 Sep 25.

PMID:
17992274
13.

Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling.

Bowen SR, van der Kogel AJ, Nordsmark M, Bentzen SM, Jeraj R.

Nucl Med Biol. 2011 Aug;38(6):771-80. doi: 10.1016/j.nucmedbio.2011.02.002. Epub 2011 May 5.

14.

Evaluation of hypoxia in a feline model of head and neck cancer using ⁶⁴Cu-ATSM positron emission tomography/computed tomography.

Ballegeer EA, Madrill NJ, Berger KL, Agnew DW, McNiel EA.

BMC Cancer. 2013 Apr 30;13:218. doi: 10.1186/1471-2407-13-218.

15.

Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).

Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ.

J Nucl Med. 2008 Feb;49(2):201-5. doi: 10.2967/jnumed.107.048520. Epub 2008 Jan 16.

16.

Cardiac hypoxia imaging: second-generation analogues of 64Cu-ATSM.

Handley MG, Medina RA, Mariotti E, Kenny GD, Shaw KP, Yan R, Eykyn TR, Blower PJ, Southworth R.

J Nucl Med. 2014 Mar;55(3):488-94. doi: 10.2967/jnumed.113.129015. Epub 2014 Jan 13.

17.

Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.

Bradshaw TJ, Yip S, Jallow N, Forrest LJ, Jeraj R.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):399-405. doi: 10.1016/j.ijrobp.2014.02.016. Epub 2014 Mar 28.

18.

Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.

McCall KC, Humm JL, Bartlett R, Reese M, Carlin S.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e393-9. doi: 10.1016/j.ijrobp.2012.05.005. Epub 2012 Jun 23.

19.

[(64)Cu]diacetyl-bis(N(4)-methyl-thiosemicarbazone) - a radiotracer for tumor hypoxia.

Wood KA, Wong WL, Saunders MI.

Nucl Med Biol. 2008 May;35(4):393-400. doi: 10.1016/j.nucmedbio.2008.02.002. Epub 2008 Apr 3. Review.

PMID:
18482676
20.

A comparison of the behavior of (64)Cu-acetate and (64)Cu-ATSM in vitro and in vivo.

Hueting R, Kersemans V, Cornelissen B, Tredwell M, Hussien K, Christlieb M, Gee AD, Passchier J, Smart SC, Dilworth JR, Gouverneur V, Muschel RJ.

J Nucl Med. 2014 Jan;55(1):128-34. doi: 10.2967/jnumed.113.119917. Epub 2013 Dec 12.

Supplemental Content

Support Center